Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. uri icon

Overview

authors

publication date

  • August 1, 2025

Identity

PubMed Central ID

  • PMC12329330

Digital Object Identifier (DOI)

  • 10.1513/AnnalsATS.202410-1045RL

PubMed ID

  • 40208257

Additional Document Info

volume

  • 22

issue

  • 8